Innovimmune Biotherapeutics
PrivateLast Round
Grant
Jul 25, 2014
Total Funding Raised
$3.65M
Company Overview
Innovimmune Biotherapeutics operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Grant round in July 2014.
Innovimmune Biotherapeutics is a biotechnology company that discovers and develops novel, first-in-class oral small molecule immunomodulatory drugs for the treatment of cancer, autoimmune diseases, and chronic inflammation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Innovimmune Biotherapeutics Comparables
Compare Innovimmune Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Matchpoint Therapeutics | 79% | |
| PIPr Therapeutics | 76% | |
| Nanjing Immunophage Biomedical Co., Ltd. | 71% |
For institutional investors. Book with your work email.
Innovimmune Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jul 25, 2014 | ||||
| Grant | Jul 9, 2014 | ||||
| Grant | Jun 13, 2012 | ||||
| Accelerator | Jan 1, 2011 |
For institutional investors. Book with your work email.
Innovimmune Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| NIH RADx | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 22, 2026
Monthly visitors increased 46% MoM.
- Jan 21, 2026
Monthly visitors increased 44% MoM.
For institutional investors. Book with your work email.
Innovimmune Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Innovimmune Biotherapeutics's valuation, stock price, and market status.
Is Innovimmune Biotherapeutics a public or private company?
Innovimmune Biotherapeutics is a private company.
What is the current stock price of Innovimmune Biotherapeutics?
Innovimmune Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Innovimmune Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Innovimmune Biotherapeutics worth (valuation)?
Valuation information for Innovimmune Biotherapeutics is not publicly available.
Can I buy Innovimmune Biotherapeutics stock?
Innovimmune Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Innovimmune Biotherapeutics's last funding round?
Innovimmune Biotherapeutics's most recent funding round was Grant on July 25, 2014.
Who are the main investors in Innovimmune Biotherapeutics?
Key investors in Innovimmune Biotherapeutics include National Institute of Allergy and Infectious Diseases, NIH RADx.
Will Innovimmune Biotherapeutics IPO soon?
No public IPO plans have been announced for Innovimmune Biotherapeutics.
How can I track Innovimmune Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Innovimmune Biotherapeutics's shares on secondary markets.